Seeing Nonmelanoma Skin Cancers Through a New Lens: The Role and Place of Immunotherapy

Activity Overview

Join our multidisciplinary experts for an interactive program offering privileged insights into the evolving nonmelanoma skin cancer (NMSC) treatment paradigm. Core topics include evidence-based strategies for identifying patients at increased risk for disease progression, pinpointing the evolution of advanced disease, and integrating immunotherapy as a key component of the armamentarium against advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC). A patient panelist augments these insights by highlighting aspects of their own treatment journey.

1.00 CE Credit(s)
Expires: June 13, 2023

Target Audience

This activity is intended for medical oncology and dermatology clinicians who manage patients with nonmelanoma skin cancer (NMSC).

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Identify patients with difficult-to-treat nonmelanoma skin cancer (NMSC) based on current staging systems, risk factors, and guidelines
  • Select appropriate immunotherapy for advanced NMSC based on available data and approved indications

Activity Faculty

Axel_Hauschild

Prof. Axel Hauschild, MD

Professor, Dermatology
Head of Dermato-oncology
Department of Dermatology
University of Kiel
Kiel, Germany

David M. Miller,

David M. Miller, MD, PhD, FAAD

Medical OncologistDermatologist
Massachusetts General Hospital
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Department of Medicine, Division of Hematology/Oncology
Department of Dermatology
Mass General Cancer Center
Boston, United States
Vishal Anil Patel

Vishal Anil Patel, MD, FAAD, FACMS

Director, Cutaneous Oncology, GW Cancer Center
Director, Dermatologic Surgery, GW Department of Dermatology
Assistant Professor, Dermatology & Hematology/Oncology
George Washington University School of Medicine & Health Sciences
Washington DC, United States

Provider Statement

This activity is provided by RMEI Medical Education, LLC

Supporter Statement

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Subscribe

Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources